Key Points Moderna has struggled since COVID-19 vaccine demand has shrunk.The stock has correspondingly declined, as revenue has nosedived over the last few years.The long game is clinical trials in ...

The 'aggressive mandate' of Covid vaccines has been blasted as a 'bad idea' by experts after a new study revealed it saved ...

Robert F. Kennedy Jr.’s leadership at Health and Human Services has led to changes in vaccine recommendations and access, ...

A series of recent changes could have significant implications for how Americans receive and pay for their shots.

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The CDC declared the end of its emergency response to H5N1 avian flu as a health threat to humans, David Murray writes.

Researchers are ushering in a new era of vaccine design that promises to be faster, more precise, and capable of tackling humanity’s most stubborn diseases.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...